Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy
Liminatus Pharma (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company focused on cancer immunotherapies, has announced the initiation of a strategic review to evaluate potential blockchain and digital asset integration into its treasury management strategy.
While maintaining its primary focus on cancer therapy development, the company is exploring regulated digital asset opportunities to optimize its balance sheet and enhance treasury efficiency for non-operating capital reserves. CEO Chris Kim emphasized that this exploratory process does not represent a shift in business focus and any future implementation would require Board approval and SEC compliance.
Liminatus Pharma (NASDAQ: LIMN), un'azienda biofarmaceutica in fase preclinica specializzata in immunoterapie oncologiche, ha annunciato l'avvio di una revisione strategica per valutare l'integrazione potenziale di blockchain e asset digitali nella sua strategia di gestione della tesoreria.
Mantenendo il suo focus principale sullo sviluppo di terapie contro il cancro, l'azienda sta esplorando opportunità regolamentate nel campo degli asset digitali per ottimizzare il proprio bilancio e migliorare l'efficienza della tesoreria per le riserve di capitale non operative. Il CEO Chris Kim ha sottolineato che questo processo esplorativo non rappresenta un cambiamento nel focus aziendale e che qualsiasi implementazione futura richiederà l'approvazione del Consiglio di Amministrazione e la conformità con la SEC.
Liminatus Pharma (NASDAQ: LIMN), una empresa biofarmacéutica en etapa preclínica enfocada en inmunoterapias contra el cáncer, ha anunciado el inicio de una revisión estratégica para evaluar la posible integración de blockchain y activos digitales en su estrategia de gestión de tesorería.
Mientras mantiene su enfoque principal en el desarrollo de terapias contra el cáncer, la compañía está explorando oportunidades reguladas de activos digitales para optimizar su balance y mejorar la eficiencia de la tesorería para las reservas de capital no operativo. El CEO Chris Kim enfatizó que este proceso exploratorio no representa un cambio en el enfoque comercial y que cualquier implementación futura requerirá la aprobación de la Junta Directiva y el cumplimiento de la SEC.
Liminatus Pharma (NASDAQ: LIMN)는 암 면역치료제에 중점을 둔 전임상 단계의 바이오제약 회사로, 자금 관리 전략에 블록체인 및 디지털 자산 통합 가능성을 평가하기 위한 전략 검토를 시작했다고 발표했습니다.
암 치료제 개발에 주력하는 가운데, 회사는 비운영 자본 준비금의 재무 상태 최적화와 자금 관리 효율성 향상을 위해 규제된 디지털 자산 기회를 모색하고 있습니다. CEO 크리스 킴은 이 탐색 과정이 사업 방향의 전환을 의미하지 않으며, 향후 도입 시 이사회 승인과 SEC 규정 준수가 필요하다고 강조했습니다.
Liminatus Pharma (NASDAQ : LIMN), une société biopharmaceutique en phase préclinique spécialisée dans les immunothérapies contre le cancer, a annoncé le lancement d'une revue stratégique afin d'évaluer l'intégration potentielle de la blockchain et des actifs numériques dans sa stratégie de gestion de trésorerie.
Tout en conservant son principal objectif de développement de thérapies contre le cancer, l'entreprise explore des opportunités d'actifs numériques réglementés pour optimiser son bilan et améliorer l'efficacité de la trésorerie pour les réserves de capitaux non opérationnels. Le PDG Chris Kim a souligné que ce processus exploratoire ne représente pas un changement d'orientation commerciale et que toute mise en œuvre future nécessiterait l'approbation du conseil d'administration ainsi que la conformité avec la SEC.
Liminatus Pharma (NASDAQ: LIMN), ein biopharmazeutisches Unternehmen in der präklinischen Phase mit Schwerpunkt auf Krebsimmuntherapien, hat die Einleitung einer strategischen Überprüfung angekündigt, um die potenzielle Integration von Blockchain und digitalen Vermögenswerten in seine Treasury-Management-Strategie zu evaluieren.
Während das Hauptaugenmerk weiterhin auf der Entwicklung von Krebstherapien liegt, prüft das Unternehmen regulierte digitale Vermögenswerte, um seine Bilanz zu optimieren und die Effizienz des Treasury-Managements für nicht operative Kapitalreserven zu verbessern. CEO Chris Kim betonte, dass dieser explorative Prozess keine Änderung des Geschäftsfokus darstellt und jede zukünftige Umsetzung die Zustimmung des Vorstands und die Einhaltung der SEC erfordern würde.
- Proactive approach to treasury management and balance sheet optimization
- Potential for enhanced capital efficiency through modern financial instruments
- Maintains commitment to core business while exploring innovative financial strategies
- Potential risks associated with digital asset exposure
- No concrete implementation plan or timeline provided
- Still in preclinical stage with no revenue-generating products
Preclinical-stage biotech company explores digital asset treasury opportunities to enhance capital efficiency while maintaining core focus on immunotherapy innovation
LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies, today announced that it has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework.
This internal review is part of Liminatus’s continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments—including blockchain-based assets—that may enhance treasury efficiency and diversify non-operating capital reserves.
“Liminatus remains fully committed to our mission of developing life-changing cancer therapies,” said Chris Kim, CEO of Liminatus Pharma, Inc. “At the same time, we believe responsible treasury management is essential to supporting our long-term goals. This review is not a shift in our business focus, but an effort to evaluate modern financial tools—such as regulated digital assets—that may enhance the way we manage non-operating capital.”
Liminatus emphasizes that this is an exploratory process only. As of today, the Company has not entered into any agreements regarding the acquisition, custody, or use of digital assets. Any potential future steps would be subject to approval by the Board of Directors and undertaken in full alignment with U.S. Securities and Exchange Commission (SEC) regulations and public company disclosure standards.
About Liminatus Pharma, Inc.
Liminatus is a preclinical-stage biopharmaceutical company developing immunotherapies for patients with cancer. The Company is advancing a pipeline of novel therapies targeting cancer antigens and tumor-specific immune responses. Liminatus is also committed to responsible innovation in capital strategy to support its long-term scientific and operational objectives.
Forward-Looking Statements
Certain statements in this press release constitute forward-looking statements. Forward-looking statements include, but are not limited to, statements regarding management’s expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. The forward-looking statements contained in this press release are based on our current expectations and beliefs concerning future developments and their potential effects. Future developments affecting Liminatus may not be those that Liminatus has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond the control of Liminatus), or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Liminatus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required under applicable securities laws.
In addition, statements that “we believe” and similar statements reflect beliefs and opinions on the relevant subject. These statements are based upon information available to Liminatus as of the date of this press release, and while Liminatus believes such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that Liminatus has conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements as predictions of future results. Liminatus’s actual future results may be materially different from what it expects. Liminatus qualifies all forward-looking statements by these cautionary statements.
Investor Relations Contact: Company Contact: Liminatus Pharma, Inc. info@liminatuspharma.com
FAQ
What is Liminatus Pharma's (NASDAQ: LIMN) new blockchain treasury initiative?
How will the blockchain treasury strategy affect Liminatus Pharma's core business?
What approvals does Liminatus Pharma need for implementing its digital asset strategy?
Has Liminatus Pharma (LIMN) already invested in digital assets?
What stage of development is Liminatus Pharma currently in?
